Stage IIIA non-small cell lung cancer represents a complex and challenging diagnosis that requires a carefully coordinated approach to treatment. Understanding your options—from standard therapies to emerging treatments being tested in research studies—can help you and your healthcare team make informed decisions about your care.

When Lung Cancer Reaches Stage IIIA: What This Means for Treatment

Stage IIIA non-small cell lung cancer occupies a unique position in the spectrum of lung cancer progression. This stage describes cancer that has spread beyond the lungs themselves but has not yet reached distant organs throughout the body. The cancer may have grown into nearby structures such as the chest wall, the diaphragm muscle that helps you breathe, or the space between the lungs called the mediastinum. It may also have spread to lymph nodes—small bean-shaped organs that are part of your immune system—on the same side of the chest as the original tumor or in the area where the windpipe divides.^[3]

About 30% of people with non-small cell lung cancer are diagnosed at stage 3, making it a relatively common presentation of this disease.^[4] What makes stage IIIA particularly challenging is that it encompasses a very diverse group of patients. Some may have small tumors with spread only to nearby lymph nodes, while others may have larger tumors invading multiple chest structures. This wide variation means that treatment plans must be highly individualized, taking into account the specific characteristics of each person’s cancer, their overall health, and their personal preferences.^[6]

The goal of treatment for stage IIIA non-small cell lung cancer is ambitious: to control or eliminate the cancer while preserving quality of life. Because the cancer has not spread to distant parts of the body, there is still an opportunity for cure or long-term control in many patients. Treatment decisions are best made through discussions with a multidisciplinary team—a group of specialists including medical oncologists, radiation oncologists, thoracic surgeons, and lung specialists who work together to develop the most effective treatment strategy.^[5]

Standard Treatment Approaches for Stage IIIA Disease

The treatment of stage IIIA non-small cell lung cancer typically involves a combination of different therapies, rather than relying on a single approach. The specific sequence and combination depend heavily on whether the cancer is considered “resectable”—meaning it can potentially be removed surgically—or “unresectable,” meaning surgery is not feasible due to the location or extent of the tumor.^[8]

Chemotherapy Combined with Radiation

For many patients with stage IIIA disease, treatment begins with chemoradiation therapy, which combines chemotherapy drugs with radiation therapy given at the same time. This combined approach is often more effective than either treatment alone. Chemotherapy involves medications that travel throughout the body to kill cancer cells, while radiation therapy uses high-energy beams to target and destroy cancer cells in specific areas of the chest.^[15]

The chemotherapy drugs most commonly used in combination with radiation therapy include cisplatin paired with etoposide. These medications work by interfering with the cancer cells’ ability to grow and divide. Cisplatin is a platinum-based drug that damages the DNA inside cancer cells, while etoposide prevents cancer cells from dividing properly. Other drug combinations that may be used include cisplatin or carboplatin paired with vinorelbine, gemcitabine, docetaxel, or paclitaxel.^[15]

The duration of chemoradiation therapy typically extends over several weeks. During this time, patients receive chemotherapy through an intravenous line (a tube inserted into a vein) while also attending daily or near-daily radiation therapy sessions. The radiation is carefully planned using imaging scans to target the tumor and affected lymph nodes while minimizing exposure to healthy lung tissue and other vital structures in the chest.^[10]

Surgery as Part of Treatment

Surgery may be an option for selected patients with stage IIIA disease, particularly when chemoradiation therapy successfully shrinks the tumor. The type of surgery performed depends on the size and location of the tumor. A lobectomy removes the lobe of the lung containing the tumor—the right lung has three lobes while the left lung has two. A pneumonectomy involves removing an entire lung and is reserved for cases where the cancer cannot be adequately treated by removing just one lobe.^[15]

More extensive operations may be necessary when the cancer has grown into surrounding structures. A sleeve resection removes a section of the airway tube (bronchus) along with the tumor, then reconnects the remaining healthy airway. An extended pulmonary resection removes the lung tissue along with involved chest wall structures such as ribs, muscles, or nerves. In some cases, surgery may involve removing parts of the diaphragm, the membrane covering the heart, or other nearby tissues if the cancer has invaded these areas.^[3]

For surgery to be considered, patients must be healthy enough to tolerate a major operation and the subsequent recovery period. Lung function tests, heart evaluations, and overall fitness assessments help determine whether surgery is a safe option. Even when surgery is technically possible, the multidisciplinary team must determine whether it is likely to provide benefit compared to continuing with other treatments.^[12]

Chemotherapy Alone

In situations where a patient cannot tolerate radiation therapy or the combination of chemotherapy and radiation together, chemotherapy may be given by itself. This approach may also be used after surgery if no chemotherapy was given before the operation, or if the cancer responded well to chemotherapy given before surgery.^[15]

The same drug combinations used with radiation therapy can also be given as standalone chemotherapy. Treatment typically involves cycles of therapy—periods of treatment followed by rest periods to allow the body to recover. Each cycle usually lasts three to four weeks, and the total duration of treatment is typically three to four cycles, though this may vary based on how the cancer responds and how well the patient tolerates the medications.^[10]

Side Effects of Standard Treatment

All cancer treatments can cause side effects, though not everyone experiences them in the same way or to the same degree. Chemotherapy side effects depend on the specific drugs used but commonly include fatigue, nausea and vomiting, loss of appetite, hair loss, increased risk of infections due to low white blood cell counts, and changes in sensation in the hands and feet called peripheral neuropathy. These side effects are usually temporary and improve after treatment ends.^[10]

Radiation therapy to the chest can cause skin irritation in the treatment area, difficulty swallowing if the esophagus (food pipe) is in the radiation field, fatigue, and inflammation of the lung tissue called radiation pneumonitis. This inflammation can cause coughing, shortness of breath, and fever. Most side effects develop gradually during treatment and typically resolve within weeks to months after radiation therapy is completed.^[10]

Surgery carries risks including infection, bleeding, air leaks from the lung, prolonged need for chest tubes to drain fluid, and in rare cases, more serious complications. Recovery from lung surgery typically requires several weeks to months, during which time breathing capacity may be reduced, particularly if a significant portion of lung tissue was removed.^[12]

Innovative Treatments Being Studied in Clinical Trials

Beyond the standard treatments described above, researchers are actively investigating new approaches to improve outcomes for patients with stage IIIA non-small cell lung cancer. These investigations take place through clinical trials—carefully designed research studies that evaluate the safety and effectiveness of new treatments before they become widely available.^[11]

Immunotherapy: Harnessing the Immune System

One of the most promising developments in lung cancer treatment involves immunotherapy, a type of treatment that helps the body’s own immune system recognize and attack cancer cells. In stage 3 non-small cell lung cancer, the immunotherapy drug durvalumab (marketed as IMFINZI) has been approved for use after chemoradiation therapy in patients whose cancer has not progressed during the combined treatment.^[4]

Durvalumab belongs to a class of drugs called immune checkpoint inhibitors. Cancer cells can disguise themselves from the immune system by activating certain “checkpoint” proteins that essentially tell immune cells to leave them alone. Durvalumab blocks one of these checkpoint proteins called PD-L1, which removes the disguise and allows immune cells to recognize and destroy cancer cells. This drug is given as an infusion into a vein, typically every two to four weeks, and may be continued for up to a year after chemoradiation therapy.^[4]

Clinical trials have shown that adding durvalumab after chemoradiation can improve outcomes for patients with unresectable stage 3 non-small cell lung cancer—those whose cancer cannot be removed with surgery. The drug has demonstrated the ability to help some patients live longer without their cancer progressing. However, immunotherapy is not appropriate for everyone, and testing of the tumor for certain biomarkers may help predict who is most likely to benefit.^[11]

Immunotherapy side effects differ from those of chemotherapy. Instead of directly damaging rapidly dividing cells, immune checkpoint inhibitors can cause the immune system to become overactive and attack normal tissues. This can lead to inflammation in various organs including the lungs, intestines, liver, hormone-producing glands, skin, and other tissues. These side effects, called immune-related adverse events, can range from mild to severe and may require treatment with corticosteroids or other immunosuppressive medications to control the immune response.^[4]

Targeted Therapy: Precision Medicine Approaches

Another major area of advancement involves targeted therapies—medications designed to attack specific molecular abnormalities that drive cancer growth. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies focus on particular genetic changes or proteins that are more common in cancer cells than in normal cells.^[15]

For patients with stage 3 non-small cell lung cancer, targeted therapy selection depends on the results of molecular testing performed on the tumor tissue. This testing looks for specific genetic mutations or alterations that can be targeted with available drugs. The most commonly targeted abnormalities include mutations in the EGFR gene (epidermal growth factor receptor) and rearrangements in the ALK gene (anaplastic lymphoma kinase).^[15]

EGFR targeted therapies include drugs such as erlotinib, gefitinib, afatinib, and osimertinib. These medications work by blocking signals that tell cancer cells with EGFR mutations to grow and divide. They are taken as pills once daily and are generally used in patients whose tumors have tested positive for specific EGFR mutations. Clinical trials are investigating whether using these drugs before surgery or in combination with other treatments can improve outcomes for patients with stage 3 disease who have EGFR mutations.^[15]

For tumors with ALK rearrangements, targeted drugs include alectinib, crizotinib, ceritinib, and brigatinib. Like EGFR inhibitors, these are oral medications that specifically block the abnormal ALK protein driving cancer growth. Other targetable alterations being studied in clinical trials include ROS1 rearrangements, BRAF mutations, MET alterations, RET fusions, and NTRK fusions, each with corresponding targeted therapies being evaluated.^[11]

The side effects of targeted therapies tend to differ from traditional chemotherapy. Common side effects include skin rash, diarrhea, nail changes, and fatigue. Some drugs can affect specific organs—for example, certain EGFR inhibitors can cause lung inflammation, while some ALK inhibitors may affect vision or cause swelling. Most side effects are manageable with dose adjustments or supportive medications, and many patients can continue their targeted therapy for extended periods.^[15]

Clinical Trial Phases and What They Mean

Clinical trials proceed through different phases, each designed to answer specific questions about a new treatment. Phase I trials are the first step in testing a new treatment in humans. These small studies, typically involving 20 to 80 participants, focus primarily on determining whether the treatment is safe, identifying the appropriate dose, and watching for side effects. Phase I trials may include patients with various types and stages of cancer.^[11]

Phase II trials enroll larger groups of participants, usually 100 to 300 people, to further evaluate safety while beginning to assess whether the treatment is effective against specific types of cancer. These trials help researchers understand how well the treatment works and continue to monitor for side effects. If a treatment shows promise in phase II, it may advance to the next stage of testing.^[11]

Phase III trials compare the new treatment to the current standard treatment or a placebo (an inactive substance). These large studies may involve hundreds to thousands of participants and are designed to definitively determine whether the new treatment is more effective than existing options, equally effective with fewer side effects, or works in a different group of patients. Phase III trials provide the evidence needed for regulatory agencies to approve new treatments for widespread use.^[11]

Emerging Approaches in Research

Researchers continue to explore additional innovative strategies for stage 3 non-small cell lung cancer. These include combining multiple immunotherapy drugs to enhance the immune response, using immunotherapy or targeted therapy before surgery to shrink tumors (called neoadjuvant therapy), and administering these treatments after surgery to eliminate remaining cancer cells (called adjuvant therapy).^[8]

Clinical trials are investigating whether giving immunotherapy along with chemotherapy and radiation therapy, rather than after these treatments, might improve outcomes. Other studies are evaluating whether adding targeted therapies to standard chemoradiation could benefit patients whose tumors have specific genetic abnormalities. The optimal duration of treatment with immunotherapy and targeted therapy in the stage 3 setting remains an active area of research.^[11]

Patient eligibility for clinical trials varies depending on the specific study. Some trials are open only to patients who have not yet received any treatment, while others accept patients who have completed initial therapy. Trials may be limited to certain age groups, performance status levels (measures of how well a patient can perform daily activities), or to patients whose tumors have specific molecular characteristics. Geographic location also matters—while some trials are available internationally, others may be limited to specific countries or regions.^[11]

Most Common Treatment Methods

• Chemoradiation Therapy
  • Combination of chemotherapy drugs such as cisplatin with etoposide, vinorelbine, gemcitabine, or other agents given alongside radiation therapy targeting the tumor and affected lymph nodes
  • Typically delivered over several weeks with daily or near-daily radiation sessions and periodic chemotherapy infusions
  • Considered a primary treatment approach for many patients with stage IIIA disease
• Surgical Resection
  • Lobectomy to remove the lobe of the lung containing the tumor
  • Pneumonectomy to remove an entire lung when necessary
  • Extended resections that may include chest wall structures, diaphragm, or other nearby tissues when the cancer has invaded these areas
  • Most appropriate for patients with resectable disease who are healthy enough to tolerate major surgery
• Immunotherapy
  • Durvalumab (IMFINZI), an immune checkpoint inhibitor that blocks PD-L1, given after chemoradiation therapy for unresectable stage 3 disease
  • Administered as intravenous infusions typically every two to four weeks for up to one year
  • Works by enabling the immune system to recognize and attack cancer cells
• Targeted Therapy
  • EGFR-targeted drugs such as erlotinib, gefitinib, afatinib, and osimertinib for tumors with EGFR mutations
  • ALK-targeted drugs such as alectinib, crizotinib, ceritinib, and brigatinib for tumors with ALK rearrangements
  • Other targeted therapies for specific genetic alterations including ROS1, BRAF, MET, RET, and NTRK abnormalities
  • Typically taken as oral medications once or twice daily
• Chemotherapy Alone
  • Drug combinations including cisplatin or carboplatin paired with etoposide, vinorelbine, gemcitabine, docetaxel, paclitaxel, or pemetrexed
  • May be used before or after surgery, or as primary treatment when radiation therapy or combined chemoradiation cannot be given
  • Typically administered in cycles of three to four weeks for a total of three to four cycles

Understanding Your Prognosis and Looking Forward

The outlook for patients with stage IIIA non-small cell lung cancer varies considerably based on many factors. These include the exact size and location of the tumor, the number and location of involved lymph nodes, whether the cancer is resectable or unresectable, the patient’s overall health and lung function, and how well the cancer responds to treatment. Five-year survival rates—the percentage of patients who are alive five years after diagnosis—range widely for stage IIIA disease, from as low as 5% in some groups to as high as 50% in others, reflecting the heterogeneity of this stage.^[6]

It is important to remember that statistics represent averages from large groups of patients and cannot predict what will happen to any individual person. Moreover, survival statistics are often based on outcomes from patients treated several years ago and may not reflect improvements from newer treatments such as immunotherapy and targeted therapy. Some patients with stage IIIA disease can achieve long-term survival and potentially be cured, particularly those whose cancer responds well to treatment and who are able to undergo complete surgical resection.^[16]

Treatment decisions for stage IIIA non-small cell lung cancer should always be made through shared decision-making between you and your healthcare team. This process involves understanding the potential benefits and risks of different treatment options, considering your personal values and preferences, and discussing practical matters such as treatment schedules and logistics. Do not hesitate to ask questions, seek a second opinion, or request clarification about any aspect of your diagnosis or treatment plan.^[5]